Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 59Myelodysplastic Syndromes 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Hodgkin Disease 49Leukemia, Lymphocytic, Chronic, B-Cell 46Leukemia 43Multiple Myeloma 41Lymphoma 41Lymphoma, Non-Hodgkin 39Lymphoma, Follicular 32Leukemia, Myelogenous, Chronic, BCR-ABL Positive 30Lymphoma, Mantle-Cell 29Lymphoma, Large B-Cell, Diffuse 29Graft vs Host Disease 29Myeloproliferative Disorders 28Congenital Abnormalities 28Lymphoma, B-Cell, Marginal Zone 27Leukemia, Myeloid, Accelerated Phase 26Leukemia, Myelomonocytic, Chronic 25Hematologic Neoplasms 24Burkitt Lymphoma 23Primary Myelofibrosis 21Neoplasms, Plasma Cell 20Waldenstrom Macroglobulinemia 19Leukemia, Myeloid, Chronic-Phase 19Blast Crisis 19Lymphoma, Large-Cell, Immunoblastic 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Anemia, Refractory, with Excess of Blasts 15Lymphoma, T-Cell, Cutaneous 14

Interventions

Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Paraneoplastic Syndromes × Tacrolimus × Clear all
NCT00378326 2023-09-18

Immunotherapy of the Paraneoplastic Syndromes

Rockefeller University

Phase NA Completed
26 enrolled 6 charts

Paraneoplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡